Knowledge Distillery

Two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), received Emergency Use Authorization from the US Food and Drug Administration.…

SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease…

In addition to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans are also susceptible to six other coronaviruses, for which…

The aim of this study was to evaluate the role of baseline lymphocyte subset counts in predicting the outcome and severity of COVID-19 patients.

Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2…

Characterizing the kinetics of the antibody response to SARS‐CoV‐2 is of critical importance to developing strategies that may mitigate the public…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve around the world, generating new variants that are of concern based…

SARS-CoV-2 variants continue to emerge during the global pandemic and may facilitate escape from current antibody therapies and vaccine protection.

The Ad26.COV2.S vaccine has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially…

Whilst SARS-CoV-2 vaccines are very safe, in this brief communication the authors report four cases of the bifacial weakness with paraesthesias…

As of April 22, 2021, around 1.5 million individuals in 3 districts of Kerala, India had been vaccinated with COVID-19 vaccines.

The objective of this study was to evaluate potential predictive factors of smell recovery in a clinical series of 288 patients presenting olfactory…